As the public health agency responsible for regulating medical products, we must ensure that health care providers have the most up-to-date diagnostics, treatments, and vaccines in their toolbox to fight this pandemic, stated the Acting Commissioner of the Food and Drug Administration (FDA) Janet Woodcock M.D.
We understand the need to adapt and pivot to support modification or development of these lifesaving tools as new coronavirus variants are identified, continued Dr. Woodcock’s excerpted statement issued on February 4, 2021.
All-Hands-On-Deck as the U.S. FDA Confronts New Coronavirus Variants
AAO-HNS Issues Guidance for Bell’s Palsy Treatment During COVID-19
Corticosteroid therapy and/or antiherpes viral therapy recommended for patients developing Bell’s palsy after vaccination
J&J Submits EUA Request for COVID-19 Vaccine
FDA committee will hold public meeting to discuss the EUA request on Feb. 26
Racial Disparities Seen in Mental Health Conditions During COVID-19
Hispanic adults reported having higher prevalence of psychosocial stress related to not having enough food or stable housing
Small Study Tests Colchicine for Moderate-to-Severe COVID-19
Authors call for larger clinical trials to further evaluate the efficacy and safety of colchicine as an adjunctive therapy for COVID-19
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 1 to 5, 2021. This …
United States Sees Continued Drop in New COVID-19 Cases
Current decline in infections most pronounced in the Midwest